Brind.

Aquestive is seeking FDA approval for a product while also filing registration statements with the SEC for a stock offering.

1 report, 1 independent Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Aquestive is seeking FDA approval for a product while also filing registration statements with the SEC for a stock offering.

Who's involved

What this event is mainly about

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • GlobeNewswireAquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock WARREN, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive”